Evaluation of serum vascular endothelial growth factor and endostatin in systemic sclerosis patients - correlation with lung and cardio-vascular system involvement

Recent studies point out the role of angiogenesis disturbances in the development of systemic sclerosis (SSc). The aim of our study was to examine vascular endothelial growth factor (VEGF) and endostatin serum levels in scleroderma patients and their correlation with skin involvement and internal organ changes. We studied 33 patients (14 with limited and 19 with diffuse SSc). The extension of skin involvement was measured using Total Skin Score (TSS). Internal organ involvement was assessed with specialistic procedures. ELISA measured serum VEGF and endostatin concentrations. We found statistically significant difference between endostatin serum levels in the control group and the patients with SSc and dSSc. Statistical analysis showed that higher VEGF levels were found in SSc and lSSc patients with changes on chest X-ray examinations, higher endostatin levels were more often observed in SSc and lSSc patients with abnormalities in cardiovascular system and in lSSc with lung dysfunction. The obtained results revealed that disturbances of angiogenesis might play a role in SSc pathogenesis. VEGF serum levels correlate with changes on chest X-ray and endostatin serum levels with abnormalities in cardiovascular system and lung dysfunction.

[1]  P. Velasco,et al.  Dermatological aspects of angiogenesis , 2002, The British journal of dermatology.

[2]  T. Robak,et al.  Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus , 2002, Lupus.

[3]  M. Kieran,et al.  Antiangiogenesis therapy. Current and future agents. , 2001, Hematology/oncology clinics of North America.

[4]  T. Robak,et al.  Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. , 2001, European cytokine network.

[5]  M. Feldmann,et al.  Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. , 2001, Arthritis and rheumatism.

[6]  A. Koch,et al.  Evidence of IL-18 as a Novel Angiogenic Mediator1 , 2001, The Journal of Immunology.

[7]  K. W. Kim,et al.  Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. , 2000, Cancer research.

[8]  G. Asano,et al.  Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. , 2000, The Journal of rheumatology.

[9]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[10]  D. Schmitt,et al.  Plasma vascular endothelial growth factor levels in scleroderma are not correlated with disease activity. , 2000, Acta dermato-venereologica.

[11]  J. Jośko,et al.  Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. , 2000, Medical science monitor : international medical journal of experimental and clinical research.

[12]  R. Maciewicz,et al.  Treatment with Soluble VEGF Receptor Reduces Disease Severity in Murine Collagen-Induced Arthritis , 2000, Laboratory Investigation.

[13]  R. Timpl,et al.  Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. , 2000, Blood.

[14]  L. Hornez,et al.  Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.

[15]  H. Ploegh,et al.  Secreted cathepsin L generates endostatin from collagen XVIII , 2000, The EMBO journal.

[16]  U. Felbor,et al.  Collagen XVIII/endostatin structure and functional role in angiogenesis. , 2000, Cell structure and function.

[17]  V. Sukhatme,et al.  Endostatin Induces Endothelial Cell Apoptosis* , 1999, The Journal of Biological Chemistry.

[18]  Krieg,et al.  Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma? , 1998, The British journal of dermatology.

[19]  Yazawa,et al.  Serum concentrations of vascular endothelial growth factor in collagen diseases , 1998, The British journal of dermatology.

[20]  W. Halfter,et al.  Collagen XVIII Is a Basement Membrane Heparan Sulfate Proteoglycan* , 1998, The Journal of Biological Chemistry.

[21]  R. Timpl,et al.  Structure, function and tissue forms of the C‐terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin , 1998, The EMBO journal.

[22]  S. Kourembanas,et al.  Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. , 1998, American journal of respiratory cell and molecular biology.

[23]  J. Jesty,et al.  Vascular endothelial groth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatininase a activation and cell proliferation , 1998 .

[24]  T. Danielsen,et al.  Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma. , 1998, British Journal of Cancer.

[25]  M. Cerinic,et al.  NEW APPROACHES TO THE TREATMENT OF RAYNAUD'S PHENOMENON , 1997 .

[26]  A. Kurtz,et al.  Induction of VEGF and VEGF receptor gene expression by hypoxia: divergent regulation in vivo and in vitro. , 1997, Kidney international.

[27]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[28]  T. Krieg,et al.  New aspects in scleroderma research. , 1996, International Archives of Allergy and Immunology.

[29]  E. Leroy.  SYSTEMIC SCLEROSIS : A Vascular Perspective , 1996 .

[30]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[31]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[32]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. , 1995, International archives of allergy and immunology.

[33]  A. Koch,et al.  Decreased monocyte-mediated angiogenesis in scleroderma. , 1992, Clinical immunology and immunopathology.

[34]  Leroy Ec,et al.  A modified scleroderma skin scoring method. , 1986 .

[35]  E. Skopińska-Różewska,et al.  Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. , 1985, Arthritis and rheumatism.

[36]  S. Jabłońska,et al.  Lowered angiogeneic capability of peripheral blood lymphocytes in progressive systemic sclerosis (scleroderma). , 1984, The Journal of investigative dermatology.

[37]  A. Reiner,et al.  Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. , 1998, Microvascular research.

[38]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.